Compare OFLX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | EOLS |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.0M | 304.0M |
| IPO Year | 2005 | 2018 |
| Metric | OFLX | EOLS |
|---|---|---|
| Price | $29.01 | $5.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 31.8K | ★ 1.4M |
| Earning Date | 06-12-2026 | 05-21-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 1.13 | N/A |
| Revenue | $101,681,000.00 | ★ $297,176,000.00 |
| Revenue This Year | N/A | $14.41 |
| Revenue Next Year | N/A | $16.96 |
| P/E Ratio | $26.50 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $25.58 | $4.09 |
| 52 Week High | $41.74 | $13.66 |
| Indicator | OFLX | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 58.52 |
| Support Level | $26.32 | $4.74 |
| Resistance Level | $29.54 | $7.29 |
| Average True Range (ATR) | 1.91 | 0.31 |
| MACD | -1.07 | 0.17 |
| Stochastic Oscillator | 22.16 | 54.65 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.